The burden of disease in seronegative myasthenia gravis: a patient-centered perspective - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40264778/
clinicaltrials.gov, identifier NCT03979521. Registered 7 June 2019 (retrospectively registered).
This study compares the burden of disease, treatment response, and quality of life in seronegative myasthenia gravis (snMG) patients to AChR antibody-positive MG patients, highlighting diagnostic delays and worse outcomes in snMG.
Progressive encephalomyelitis with rigidity and myoclonus after thymectomy in a woman with myasthenia gravis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40308612/
Progressive encephalomyelitis with rigidity and myoclonus (PERM), part of the spectrum of stiff-person syndrome (SPS), is a rare neurological disorder characterized by axial and limb rigidity, painful muscle spasms, hyperekplexia,...
This case report describes a woman with myasthenia gravis who developed Progressive Encephalomyelitis with Rigidity and Myoclonus (PERM) after thymectomy. The patient improved with immunosuppressive therapy, highlighting the need for early diagnosis.
Case report: A highly active refractory myasthenia gravis with treatment of telitacicept combined with efgartigimod - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38799457/
There is always a lack of effective treatment for highly active refractory generalized myasthenia gravis (GMG). Recently, telitacicept combined with efgartigimod significantly reduces circulating B cells, plasma cells, and immunoglobulin...
A 37-year-old woman with refractory generalized myasthenia gravis showed marked improvement using telitacicept and efgartigimod after failed treatments, highlighting this combination's potential as a promising therapeutic strategy.
Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38117543/
gMG has a physical, mental, and social impact, resulting in a considerable burden of disease and substantially decreased QoL, despite standard treatments. The availability of novel, targeted treatments that influence...
This narrative review highlights the burden and complexity of generalized myasthenia gravis (gMG), emphasizing evolving therapies, patient profiling, and the need for standardized assessments to improve individualized treatment and outcomes.
A Case of Pediatric Myasthenia Revealed by Marked Eyelid Ptosis After Using Cyclopentolate Eye Drops - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40177434/
Pediatric myasthenia gravis (PMG), while uncommon, poses significant diagnostic challenges due to its potential impact on development and its often subtle initial symptoms, such as ptosis and diplopia. This case...
https://pubmed.ncbi.nlm.nih.gov/40177434/
A three-year-old girl’s persistent ptosis, initially mistaken for a chalazion, led to a pediatric myasthenia gravis diagnosis, emphasizing early recognition, caregiver observations, and comprehensive pediatric ophthalmologic evaluations.